DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Thursday. The firm issued a hold rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Stock Down 4.2 %

DBVT stock opened at $4.26 on Thursday. The firm has a market cap of $87.52 million, a price-to-earnings ratio of -0.95 and a beta of 0.67. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $9.09. The company’s fifty day simple moving average is $4.20 and its 200 day simple moving average is $3.82.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.